Bio-Techne (NASDAQ:TECH) Hits New 52-Week Low After Earnings Miss

Key Points

• Bio-Techne shares fell to a new 52-week low after quarterly results missed estimates — adjusted EPS $0.53 vs. $0.55 expected and revenue $311.4M vs. $316.1M, a ~1.5% year‑over‑year decline.
• Management cited weaker demand from U.S. academic funding cuts and the timing of large Commercial Supply shipments (plus prior‑year GMP fast‑track orders) as key drivers of the quarter’s softness and the resulting selling pressure.
• The board declared a $0.08 quarterly dividend (annualized $0.32, ~0.7% yield), while analysts remain mostly positive with a consensus "Moderate Buy" rating and an average price target of $72.77.

Bio-Techne Corp (NASDAQ:TECH - Get Free Report)'s stock price reached a new 52-week low on Thursday after the company announced weaker than expected quarterly earnings. The company traded as low as $45.12 and last traded at $47.2550, with a volume of 11948129 shares changing hands. The stock had previously closed at $56.68.

The biotechnology company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.02). Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. The company had revenue of $311.42 million during the quarter, compared to the consensus estimate of $316.11 million. During the same period last year, the firm posted $0.56 earnings per share. The company's revenue for the quarter was down 1.5% on a year-over-year basis.

Bio-Techne Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Monday, May 18th will be given a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Monday, May 18th. Bio-Techne's payout ratio is presently 62.75%.

Key Headlines Impacting Bio-Techne

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Operating profitability improved and some growth vectors remain strong — GAAP EPS rose to $0.32 from $0.14 a year ago, adjusted EPS was $0.53, and segments like Spatial Biology, Proteomic Analysis instruments and GMP proteins showed mid‑single to high‑double digit growth. Bio-Techne Releases Third Quarter Fiscal 2026 Results
• Positive Sentiment: Board declared a quarterly cash dividend of $0.08 per share (payable May 29; yield ~0.7%), which supports income investors and signals capital-return discipline. Bio-Techne Declares Dividend
• Neutral Sentiment: Earnings call transcript and company materials are available for deeper detail on guidance, shipment timing and customer behavior — useful for assessing whether weakness is transient. Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst coverage shows mixed price targets (wide range) and continued interest from institutional holders — implies varied views on recovery vs. structural demand weakness. Quiver Quant Coverage
• Negative Sentiment: Revenue and adjusted EPS missed consensus: revenue $311.4M vs. ~$316M estimate (reported down ~1.5–2% YoY) and adjusted EPS $0.53 vs. $0.55 consensus — the top‑line shortfall is the main trigger for selling pressure. TECH Stock Falls on Q3 Earnings & Revenue Miss
• Negative Sentiment: Management cited weaker demand from U.S. academic funding cuts and the timing of large Commercial Supply shipments plus prior‑year GMP fast‑track orders as drivers of the quarter’s softness — risks that could persist near term. Bio-Techne misses revenue estimates — Reuters

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TECH. Robert W. Baird set a $70.00 price objective on Bio-Techne in a research note on Thursday, February 5th. TD Cowen reaffirmed a "buy" rating on shares of Bio-Techne in a research report on Tuesday, March 17th. UBS Group reiterated a "buy" rating and issued a $79.00 target price (up from $70.00) on shares of Bio-Techne in a report on Thursday, February 5th. Citigroup reissued a "buy" rating and issued a $80.00 price target (up from $70.00) on shares of Bio-Techne in a research report on Wednesday, February 4th. Finally, Wells Fargo & Company boosted their price target on shares of Bio-Techne from $70.00 to $76.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $72.77.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Danske Bank A S bought a new stake in Bio-Techne during the fourth quarter worth $29,000. eCIO Inc. bought a new position in Bio-Techne during the 4th quarter valued at $30,000. Measured Wealth Private Client Group LLC purchased a new position in Bio-Techne during the 3rd quarter worth $32,000. iSAM Funds UK Ltd purchased a new position in Bio-Techne during the 3rd quarter worth $33,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Bio-Techne by 506.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 562 shares in the last quarter. Institutional investors own 98.95% of the company's stock.

Bio-Techne Stock Performance

The company's 50 day moving average price is $54.55 and its 200-day moving average price is $59.61. The stock has a market cap of $7.39 billion, a P/E ratio of 92.66, a price-to-earnings-growth ratio of 3.73 and a beta of 1.41. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.08 and a current ratio of 4.54.

About Bio-Techne

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.